Cisplatin-induced non-convulsive encephalopathy

Anti-Cancer Drugs

Volumn 9, Issue 1, 1998, Pages 100-104

  Lyass, Olga ^a   Lossos, Alexander ^a   Hubert, Ayala ^a   Gips, Maya ^a   Peretz, Tamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Adverse effect; Cisplatin; Encephalopathy

Indexed keywords

CISPLATIN;

AGED; ARTICLE; BLOOD VESSEL INJURY; BRAIN DISEASE; CANCER CHEMOTHERAPY; CASE REPORT; CONFUSION; ELECTROENCEPHALOGRAM; EPILEPTIC DISCHARGE; FEMALE; HOMONYMOUS HEMIANOPIA; HUMAN; HYPESTHESIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY ADENOCARCINOMA; PRIORITY JOURNAL;

EID: 0031952133     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199801000-00013     Document Type: Article

References (17)

1. Reed E. Platinum analogs. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of Oncology. Philadelphia, PA: Lippincott 1997: 418-21.
2. Von Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 1979; 63: 1527-31.
3. Lossos A, Siegal T. Electric shock-like sensations in 42 cancer patients: clinical characteristics and distinct etiologies. J Neuro-Oncol 1996; 29: 175-81.
4. Berman IJ, Mann MP. Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty year old man. Cancer 1980; 45: 764-66.
5. Mead GM, Arnold AM, Green JA, et al. Epileptic seizures associated with cisplatin administration. Cancer Treat Rep 1982; 66: 1719-22.
6. Hitchins RN, Thomson DB. Encephalopathy following cisplatinum, bleomycin and vinblastine therapy for non-seminomatous germ cell tumor of testis. Aust NZ J Med 1988; 18: 67-8.
7. Gorman DJ, Kefford R, Stuart-Harris R. Focal encephalopathy after cisplatin therapy. Med J Aust 1989; 150: 399-401.
8. Nomura K, Ohno R, Hamaguchi K, et al. Clinicopathological report of cisplatin encephalopathy. Rinsho-Shinkeigaku 1995; 35: 64-9.
9. Pippitt CH, Muss HB, Homesley HD, et al. Cisplatin-associated cortical blindness. Gynecol Oncol 1981; 12: 253-5.
10. Diamond SB, Rudolph SH, Lubicz SS, et al. Cerebral blindness in association with cis-platinum chemotherapy for advanced carcinoma of the fallopian tube. Obstet Gynecol 1982; 59(S): 84-6.
11. Cohen RJ, Cuneo RA, Cruciger MP, et al. Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine and bleomycin. J Clin Oncol 1983; 1: 392-3.
12. Higa GM, Wise TC, Crowell EB. Severe, disabling neurologic toxicity following cisplatin retreatment. Ann Pharmacother 1995; 29: 134-7.
13. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther 1981; 30: 239-45.
14. Kastrup O, Diener HC. Granulocyte-stimulating factor filgrastim and molgramostim induced recurring encephalopathy and focal status epilepticus. J Neurol 1997; 244: 274-5.
15. Snodgras SM, Tsuburaya K, Ajmone-Marsan C. Clinical significance of periodic lateralized epileptiform discharges: relationship with status epilepticus. J Clin Neurophysiol 1989; 6: 159-72.
16. Gregg RW, Molepo JM, Monpetit VJA, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795-803.
17. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Eng J Med 1996; 334: 494-500.